

Supramolecules in Cancer Selective Chemotherapy

Type: Short Communication

Received: March 03, 2025

Published: April 02, 2025

Citation:

Seema Kothari. "Supramolecules in Cancer Selective Chemotherapy". PriMera Scientific Medicine and Public Health 6.4 (2025): 23-24.

Copyright:

© 2025 Seema Kothari. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Seema Kothari*

PAHER University, Udaipur (Raj.) India

***Corresponding Author:** Seema Kothari, PAHER University, Udaipur (Raj.) India.

Supramolecules in chemotherapy refer to larger, complex structures formed by non-covalent interactions between molecules, often used in drug delivery systems or as therapeutic agents themselves. These structures can enhance the effectiveness and specificity of chemotherapy treatments by enabling more targeted drug delivery, improving the pharmacokinetics, and minimizing side effects.

Key Roles of Supramolecules in Chemotherapy:

Drug Delivery Systems

- Supramolecular assemblies can encapsulate chemotherapy drugs, improving their solubility and stability.
- They help target drugs directly to cancer cells by taking advantage of specific interactions with cancer cell markers, reducing the impact on healthy cells.
- Examples include liposomes, micelles, and nanoparticles, which are all forms of supramolecular systems that can deliver chemotherapy agents in a controlled and sustained manner.

Targeting

- Supramolecular complexes can be engineered to recognize specific cancer biomarkers or over-expressed receptors on tumor cells. This targeting ability reduces the need for chemotherapy drugs to circulate throughout the body, thereby decreasing systemic toxicity and side effects.

Controlled Release

- Some supramolecular systems can release chemotherapy drugs in response to specific triggers, such as changes in pH, temperature, or the presence of certain enzymes. This feature allows for localized and controlled release of the drug, ensuring it acts primarily on the tumor.

Reducing Drug Resistance

- By modifying the structure of the supramolecule or the way it interacts with the chemotherapy agent, it's possible to overcome mechanisms of drug resistance that cancer cells develop. This could be done by preventing the drug from being expelled from the cell or by improving drug uptake.

Examples of Supramolecular Systems in Chemotherapy:

- *Cyclodextrins*: These are cyclic oligosaccharides that can form supramolecular complexes with chemotherapy drugs, improving their solubility and stability in the body.

- *Polymeric Micelles*: These self-assembled nanoparticles have hydrophobic cores that can encapsulate hydrophobic drugs, enhancing drug solubility and prolonging circulation time.
- *Dendrimers*: These are branched, tree-like macromolecules that can carry multiple drug molecules on their surface, offering both targeted delivery and controlled release.

Advantages of Supramolecular Systems in Chemotherapy

- *Targeted drug delivery*: By directing drugs specifically to cancer cells, supramolecules reduce harm to healthy tissues.
- *Improved solubility and stability*: Many chemotherapy drugs are poorly soluble in water, which can limit their effectiveness. Supramolecular complexes can enhance drug solubility and stability, improving their bioavailability.
- *Reduced toxicity*: By controlling the release and targeting of chemotherapy agents, supramolecules help minimize the systemic toxicity typically associated with chemotherapy.

Challenges

- *Complex synthesis and design*: Engineering supramolecular systems for specific drug delivery can be complex and costly.
- *Long-term safety*: The long-term safety of these delivery systems is still under investigation, as their breakdown products in the body need to be carefully considered.

In summary, supramolecules are an exciting field in cancer chemotherapy, offering the potential for more effective, targeted, and less toxic treatment options. Research is ongoing to improve the design, functionality, and clinical application of supramolecular systems in cancer therapy.